Ariad Goes From Bad to Worse to Worst

Things have gone from bad to worse to worst for Ariad Pharmaceuticals (NASDAQ: ARIA  ) . Its one-month stock chart resembles stairs down to the Grand Canyon.

ARIA Chart

ARIA data by YCharts.

The first drop happened when Ariad announced that it continued to see blood clots in patients taking its blood cancer drug Iclusig. The drug is currently approved as a second-line or later treatment after patients have already been treated with Novartis' (NYSE: NVS  ) Gleevec or Bristol-Myers Squibb's (NYSE: BMY  ) Sprycel.

As a treatment of last resort, a risky safety profile could be acceptable, but Ariad was valued as high as it was before the news because investors were counting on Iclusig getting approved as a first-line leukemia treatment. Being used before Novartis' or Bristol-Myers Squibb's drugs could have made Iclusig a blockbuster.

Ariad was testing Iclusig head to heat against Gleevec in a trial dubbed Epic, but the biotech paused enrollment in the trial when the safety issue was announced earlier this month.

Ariad eventually came to the conclusion that the Epic trial wasn't worth continuing. That second dip in the middle of the month doesn't look all that bad, but that's only because of the scale. It's actually a 59% haircut.

Which brings us to today, when ARIAD fell another 44% after announcing that the FDA wants Ariad to temporarily stop marketing and commercial distribution of Iclusig.

While it's pretty bad news, Ariad believes there's a good chance the FDA will eventually allow patients to use the drug again. There's likely a population where the benefit from taking Iclusig outweighs the risk of blood clots.

Until the FDA and Ariad define that population and how they're going to keep other risky patients from taking Iclusig, the FDA wants to limit access to the drug. Essentially, the FDA is saying that doctors are idiots and don't do enough research into drugs they prescribe.

Eventually, the FDA and Ariad will rewrite the label and establish an Elements To Assure Safe Use, or ETASU, which could be as simple as educating doctors before they prescribe the drug, but might include something more complex like a patient registry.

Ariad doesn't know how long that'll take. My guess is a month or more to write up the new plan plus a few months to actually implement it. If the FDA decides it needs help from outside experts, it'll take much longer to schedule an advisory committee meeting.

Keep in mind there's always the possibility that the FDA will conclude that it's too hard to define the risk-benefit and pull the drug completely off the market until Ariad runs clinical trials to establish the best population to be treated with Iclusig.

Or in other words, there could still be another step down. Ariad is, after all, is still a decently sized company with a $400 million market cap.

Good, better, best
Not every biotech is experiencing bad news. The Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," reports on two companies with a new technology that big pharma is endorsing through partnerships, set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 31, 2013, at 7:53 PM, prginww wrote:


    I reluctantly agree with your assessment -- bad to worse. But Worst? I do think, however, that Ariad management believes that the FDC overshot with their suspension recommendation. The adverse events were largely known at the time of the NDA. So, why suddenly so bad? Most of the patients on Iclusig really have no alternative. So, let's REMS up a plan and get the puppy back onto the market. That said, clearly first line use of Iclusig is off the table as well as Ariad's former very lofty market cap. But, I just don't see the 'worst' case... We'll know more on the CC on the 12th.


  • Report this Comment On October 31, 2013, at 10:34 PM, prginww wrote:

    somebody want's to buy Ariad cheap!

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2708587, ~/Articles/ArticleHandler.aspx, 10/1/2016 1:15:32 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 hours ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 4:00 PM
ARIA $13.69 Down -0.02 -0.15%
Ariad Pharmaceutic… CAPS Rating: **
BMY $53.92 Up +0.05 +0.09%
Bristol-Myers Squi… CAPS Rating: ****
NVS $78.96 Down -0.29 -0.37%
Novartis CAPS Rating: ****